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Abstract
Background: Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly
potent in cell culture and efficacious in HIV-1 infected patients. In contrast to inhibitors that target the active site
of the viral protease, bevirimat specifically inhibits a single cleavage event, the final processing step for the Gag
precursor where p25 (CA-SP1) is cleaved to p24 (CA) and SP1.
Results: In this study, photoaffinity analogs of bevirimat and mass spectrometry were employed to map the
binding site of bevirimat to Gag within immature virus-like particles. Bevirimat analogs were found to crosslink to
sequences overlapping, or proximal to, the CA-SP1 cleavage site, consistent with previous biochemical data on the
effect of bevirimat on Gag processing and with genetic data from resistance mutations, in a region predicted by
NMR and mutational studies to have a-helical character. Unexpectedly, a second region of interaction was found
within the Major Homology Region (MHR). Extensive prior genetic evidence suggests that the MHR is critical for
virus assembly.
Conclusions: This is the first demonstration of a direct interaction between the maturation inhibitor, bevirimat, and
its target, Gag. Information gained from this study sheds light on the mechanisms by which the virus develops
resistance to this class of drug and may aid in the design of next-generation maturation inhibitors.
Background
Despite the significant progress in the development of
therapeutics against Human Immunodeficiency Virus
type 1 (HIV-1), resistance to existing drugs is a continu-
ing challenge for clinical management [1,2]. Therefore,
new anti-HIV-1 agents are constantly needed. Bevirimat
(BVM), previously called DSB [3], PA-457 [4], or YK-
FH312 [5] potently inhibits HI V - 1r e p l i c a t i o ni nt i s s u e
culture and is efficacious in HIV-1 infected patients
[4,6,7]. Bevirimat (3-O-(3’3’-dimethylsuccinyl)betulinic
acid) was developed by activity-directed derivatization of
betulinic acid, a plant-derived natural product [8]. Betu-
linic acid itself has only modest anti-HIV-1 activity, but
the addition of a dimethylsuccinyl side chain at position
3 of betulinic acid enhanced its anti-HIV-1 activity
1000-fold [9]. Bevirimat is active against a wide variety
of HIV-1 isolates, including those that are resistant to
protease inhibitors [4]. Biochemical analyses of virus
particles grown in the presence of bevirimat display a
defect in capsid (CA)-spacer peptide 1 (SP1) processing.
Electron microscopy revealed that such particles are
aberrant, lacking a matured conical core and with a dis-
tinct electron dense immature morphology-like layer
beneath the viral membrane [4,10].
The ability of bevirimat to affect only a single cleavage
site in the Gag substrate suggests that Gag, rather than
the protease enzyme, is the target of inhibition [11].
HIV-1 Gag is the main structural component of the vir-
ion [12,13]. After synthesis on free polysomes in the
cytoplasm, myristylated Gag molecules are transported
to the inner leaflet of the plasma membrane, where they
polymerize and form budding structures that eventually
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budding and maturation are tightly linked, with activa-
tion of the protease coupled to, and potentially facilitat-
ing, release of the particle [15]. Maturation of the
particle is required for infectivity and is accompanied by
a dramatic morphological reorganization of the virion,
from the spherical immature capsid with an electron
lucent center, to the mature particle containing the cen-
tral conical core [16-18]. The Gag precursor polyprotein
is divided into sub-domains: Matrix(MA)-Capsid(CA)-
SP1-Nucleocapsid(NC)-SP2-P6. The viral protease
cleaves Gag in a specific order likely resulting from dif-
ferent inherent cleavage rates at each site [19] MA-CA-
SP1 is first separated from NC-SP2-P6 at amino acid
377. Subsequent cleavages remove MA from CA-SP1
(C-terminal to amino acid 132), P6 from NC-SP2
(amino acid 448), and NC from SP2 (amino acid 432).
The final cleavage separates SP1 from CA (amino acid
363). After maturation, the separated domains of Gag
reorganize: the matrix protein (MA) remains associated
with the viral membrane, possibly as a trimer [20], with
the N-terminal portion interacting with the cytoplasmic
tail of envelope, thereby in the context of full length
Gag, allowing recruitment of envelope glycoprotein into
the virion [21,22]; the capsid (CA) proteins assemble to
form the conical core [23]; and the nucleocapsid (NC)
protein associates with the viral genomic RNA, with
which it condenses to form the nucleoprotein. The
remaining portions of Gag: SP1, SP2, and p6, have no
known functions within the mature virion. However, p6,
as a part of the Gag precursor, interacts with Tsg101 to
facilitate budding from the cell surface [24,25], and SP1
w a sp r o p o s e dt of u n c t i o na sam o l e c u l a rs w i t c ht h a t
controls viral maturation [26].
The role for SP1 as a maturation regulator was initi-
ally proposed from studies where it was found that the
rate of cleavage at the CA-SP1 junction could be modu-
lated by changes at the SP1-NC cleavage site [27,28].
Studies to relate the structure of SP1 to its function
have been hampered by the inability to observe order in
this region in crystal structures [29,30]. Mutational ana-
lyses and modeling suggested that a helical conforma-
tion is important, as point mutations predicted to
reduce helical character abrogate particle production
[31,32]. NMR studies of a Gag fragment comprised of
the C-terminal half of CA, SP1, and NC indicated that
this region is in equilibrium between a random coil and
a helical state [33]. Subsequent NMR analysis of pep-
tides spanning the SP1 region confirmed the helical nat-
ure of this region, but required solvent conditions
conducive to helix formation [34]. Recent cryo-electron
tomography of immature particles indicated that SP1
forms a distinct hexameric lattice beneath the hexameric
lattice formed by CA and that the density corresponding
to SP1 can be fitted as a six-helix bundle. This model
further suggested a mechanism by which SP1 acts as a
molecular switch, whereby, following processing by the
viral protease to liberate SP1 from CA, the capsid C-
terminal domains extend out to make homodimeric
contacts with neighboring hexamers [26]. This results in
hexameric ring expansion and opening of the lattice in
the mature core, as observed in several cryo-electron
microscopy studies of mature assembled CA structures
[17,23].
Extensive mutational studies have pinpointed the role
of the CA-SP1 junction sequence in determining beviri-
mat activity. Substitution of SIV-specific residues into
the CA-SP1 cleavage site of HIV-1 blocked inhibitor
activity [35]. Since SIV is not susceptible to inhibition
by bevirimat, these results suggested that bevirimat
interacts directly with the HIV-1 sequence in the region
of the CA-SP1 cleavage site. This idea is supported by
the results of an extensive effort to develop resistance
mutants in vitro to bevirimat [10]. Resistance could be
conferred by changes at positions flanking the CA-SP1
cleavage site [reviewed in 11], with a change of alanine
to valine in the P1’ position arising most frequently, and
also by polymorphisms within the QVT motif [36-38],
while no changes were found in the sequence of the
viral protease. These data suggested it should be rela-
tively simple to replicate the activity of bevirimat in
vitro with soluble recombinant Gag. However, attempts
to do so failed [4], leading to the idea that the assembly
state of Gag is a determinant for activity. This was con-
firmed by use of a cell-free assembly system, in which
HIV-1 Gag has been modified to assemble into imma-
ture virus-like structures following in vitro translation
that are susceptible to bevirimat inhibition of matura-
tion [39].
Clearly, if the activity of bevirimat requires assembled
Gag, then inhibition cannot simply result from recogni-
tion of the primary sequence of the CA-SP1 cleavage
site. While it has been demonstrated that the inhibitor
can be incorporated into whole particles [40], there has
been no direct evidence that bevirimat interacts directly
with the CA-SP1 cleavage site of Gag. In an effort to
further characterize the target of bevirimat, we have
used photoaffinity crosslinking to covalently link beviri-
mat analogs to immature assembled Gag. Mass spectro-
metry was then used to determine the regions of adduct
formation within the protein. We report here the first
direct evidence that bevirimat binds to its target HIV-1
Gag at the CA-SP1 junction. Additionally, because we
used two photoaffinity analogs with different spacer arm
lengths located at different positions on the triterpene
backbone, it was possible to further characterize beviri-
mat’s interaction site and its orientation relative to the
target. In vitro-selected, bevirimat-resistant Gag mutants
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thetic mutant (ΔM377) were also examined for the abil-
ity and location of analog binding and the results
support the proposed binding mode of bevirimat.
Results
Production and preparation of detergent-stripped
immature HIV-1 virus-like particles
Since previous analyses in cell free assays showed that
bevirimat acts only in the context of assembled Gag
[39], it was necessary to produce immature virus-like
particles (VLP) to conduct our study. To generate suffi-
cient material for analysis, we performed large-scale
transfections of the immature particle-producing plas-
mid pVP-I into 293T cells. Immature particles released
into the medium were filtered, purified, and collected as
described. At this stage, the viral particles were heavily
contaminated with fetal bovine serum (BSA) and other
cellular debris as determined by Coomassie blue staining
(Figure 1A). However, after stripping the membrane
from the particles with mild detergent and collecting
the resulting immature VLP through a discontinuous
sucrose gradient, we were able to remove most of the
contaminating proteins (Figure 1B). The amount of Gag
in the particle preparation was quantified using a BSA
standard curve run in parallel on the gel. Approximately
30 μgo fH I V - 1G a gp r o t e i nw a su s e dp e rc r o s s l i n k i n g
experiment.
Creation of a peptide map for HIV-1 Gag after protease
digestion
Since our aim was to identify the location of bevirimat
binding site by identification of the adduct-containing
peptides after protease digestion of particles, it was first
necessary to perform these digestions on native Gag
particles and identify the potential peptides. The result-
ing map of Gag peptides would then be used to identify
the changes due to analog adducts and thus the binding
region for bevirimat. Purified viral cores were subjected
to reduction, alkylation, and protease digestion. The
digestion reaction mixture was then subjected to HPLC/
MALDI analysis. In order to get unambiguous identifi-
cation of peptide fragments, which is critical for identi-
fying the peptide/analog adducts, we reduced the
complexity of the peptide mixture by using a shallow
acetonitrile step gradient (15% to 65% in 80 minutes)
and collecting small volume fractions (150 μl/fraction)
from the reverse phase HPLC column. All identified
peptide fragments of HIV-1 Gag after Lys-C, Glu-C and
Arg-C protease digestion are shown in Figure 2. Peptide
fragments covering 95.2% of the entire HIV-1 Gag pro-
tein sequence were identified. To simplify our analysis,
only completely digested peptide fragments were used
to construct the peptide map; partial cleavage products
were excluded. Details of the mass spectra analyses of
all identified peptide fragments, including signal-to-
noise ratio, relative intensity, and area under the
observed peak, were analyzed and recorded (Additional
File 1: Additional Table 1). The removal of the first
methionine and the addition of myristic acid were taken
into account for mass determination of the N-terminal
Gag peptide [20]. Peptide fragments smaller than 1000
daltons were difficult to identify due to the presence of
the overlapping spectra of matrix ions. Peptide frag-
ments larger than 5000 daltons were also rarely found,
since large peptides were not ionized sufficiently to be
detected using our MALDI-TOF instrument. Neverthe-
less, we were able to achieve excellent coverage and the
data were complete for more than 100 amino acids each
side of the region of interest, the CA-SP1 junction.
Testing the activities of the photo-affinity bevirimat
analogs
The structures of the two photoaffinity analogs of bevir-
imat used in this study are shown in Figure 3A. The C-
28 analog has the azido photoreactive group attached to
a tetrafluorobenzyl piperazine amide bound to carbon
28. The C-30 analog has the azide photo-reactive group
attached directly to carbon 30. The IC50 of these analogs
were determined to be similar to that of bevirimat by
MT2 cell killing end point assay with virus isolate HIV-
1lllB a t1 . 1n Mf o rt h eC - 2 8a n a l o ga n d4 . 7n Mf o rt h e
C-30 analog as compared to 1.3 nM for bevirimat.
Figure 1 Detergent-stripped immature HIV-1 virus-like particle
purification. (A) Coomassie blue staining of SDS-PAGE of immature
VLP before detergent treatment. (B) Coomassie blue staining of
SDS-PAGE of immature particles after detergent treatment. Pr55 Gag
and bovine serum albumin (BSA) are indicated by the arrows.
Volumes of particle sample and nanograms of BSA standards are
given at the top.
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irimat at these positions does not significantly affect
activity [8]. These results indicate that the addition of
the photoaffinity groups does not appreciably alter the
activity of these analogs in the whole cell assay.
To test the photo-affinity chemistry of the bevirimat
analogs we first attempted to crosslink each analog to
the synthetic peptide GVGGPGHKARVLAEAMSQVTN-
PATI spanning the CA-SP1 region. Initial experiments
were performed under aqueous conditions with the syn-
thetic peptide dissolved in either pure water or PBS.
Using MALDI-TOF mass spectrometry, we were unable
to detect any peptide/analog adducts. Since the CA-SP1
region may form an alpha helix [31,32], which could be
critical for bevirimat binding in the context of
assembled Gag, we then conducted the crosslinking
experiment in 50% trifluoroethanol (TFE) in PBS. Tri-
fluoroethanol is a nonpolar solvent that promotes heli-
city in peptides by desolvating the peptide backbone,
thereby indirectly strengthening intra-helical hydrogen
bonds [41]. Peptide/analog adducts were detected for
the C-28 analog (Figure 3B) and evidence for such
adducts for the C-30 analogs could be seen in the spec-
tra, but the signal:noise ratio was low and we did not
use this data. The theoretical monoisotopic mass of the
synthetic peptide/C-28 analog adduct is 3302.79 Da,
which matches the monoisotopic mass of the ion
detected. This result not only indicated that the chemis-
try of the crosslinking reaction performed as expected,
but also that crosslinking was more efficient when the
peptide was in a helical conformation, suggesting that
interaction of the analog with the peptide was greater
under these conditions. Nevertheless, the relative abun-
dance of non-crosslinked peptide in the reaction mix-
ture was 1000 fold higher than crosslinked peptide (data
not shown), which indicates the crosslinking reaction
was extremely inefficient. We also observed a large pro-
portion (~99%) of both analogs crosslinked to DMSO,
MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQI

                                                         120
LGQLQPSLQTGSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAA

                                                         180
DTGNNSQVSQNYPIVQNLQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGAT

                                                         240
PQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTT

                                                         300
STLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRF

                                                         360
YKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTACQGVGGPGHKA

                                                         420
RVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG

                                                         480
HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPID


KELYPLASLRSLFGSDPSSQ

Lys-C 
Glu-C 
Arg-C 
Figure 2 Peptide map of HIV-1 Gag after Arg-C, Glu-C, and Lys-C protease digestions. Only fully digested peptide fragments are shown.
SP1 sequence is indicated in red. Black arrowhead points to the CA-SP1 cleavage site.
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abundance of this side reaction could also have contrib-
uted to the low efficiency of crosslinking to the peptide
under all conditions, but since bevirimat does not inhi-
bit cleavage of unassembled Gag, the low reactivity of
cross-linking is not surprising.
Mapping bevirimat analog interaction with HIV-1 Gag
within immature particles
After confirming that both analogs possessed photoacti-
vated crosslinking activity to at least DMSO and for the
C-28 analog also to the synthetic peptide, we performed
crosslinking experiments in the context of immature
HIV-1 VLP. Mass spectrum details for C-28 infused and
protease digested particles, incubated under either UV
exposed or non-exposed conditions, were recorded and
examined (Additional File 1: Additional Table 2). Fol-
lowing the crosslinking, the reaction products were
digested with each of three proteases, Lys-C, Arg-C, and
Glu-C. Experiments with the C-28 analog followed by
Lys-C digestion were conducted twice. In both experi-
ments, we observed two regions of C-28 crosslinking.
Consistent with expectations given by all previous data
on the bevirimat mechanism of action, we identified a
peptide-analog adduct within the C-terminal region of
CA just upstream from the CA-SP1 cleavage site com-
prising amino acid residues 336 to 359 of Gag (ALGP-
GATLEEMMTACQGVGGPGHK, Figure 4A).
Unexpectedly, we also found a second peptide-analog
adduct, within residues 291 to 302 (EPFRDYVDRFYK,
Figure 4B), that lies within the Major Homology Region
(MHR). The monoisotopic masses of these ions matched
the theoretical monoisotopic masses of C-28/peptide
adducts (Table 1).
In contrast to the Lys-C digestion experiments, diges-
tions with both Glu-C and Arg-C yielded crosslinked C-
C-28 analog C-30 analog
A 
B 
11 Å 
2.5 Å 
Bevirimat
3
28 
30 
C-28 analog
Figure 3 Photoaffinity bevirimat analogs. (A) Structures of bevirimat and the photoaffinity analogs. (B) Detail of mass spectra showing ion
mass corresponding to the C-28 analog crosslinked to a synthetic peptide spanning the CA-SP1 region. Red and blue traces are spectra derived
from the crosslinking reaction performed in 50% TFE or pure water, respectively. The theoretical monoisotopic mass of the synthetic peptide/C-
28 analog adduct is 3302.79: monoisotopic mass of peptide + monoisotopic mass of C-28 - mass of N2 gas + mass of proton = 2460.29 + 869.5
- 28 + 1 = 3302.79 Da, which is in good agreement with the monoisotopic mass of the ion shown.
Nguyen et al. Retrovirology 2011, 8:101
http://www.retrovirology.com/content/8/1/101
Page 5 of 1328 peptides corresponding to only one region of Gag.
Glu-C digestion yielded only a peptide within the MHR,
residues 292 to 307 (PFRDYVDRFYKTLRAE, Figure
4C). A theoretical peptide adduct including the CA-SP1
cleavage site (MMTACQGVGGPGHKARVLAE) was not
observed. Likewise, Arg-C digestion of crosslinked C-28/
Gag similarly yielded a peptide within the MHR, resi-
dues 295-299 (DYVDR, Figure 4D). A theoretical Arg-C
peptide overlapping the region of CA found for the Lys-
C digestion was also not observed, but in this case the
large peptide (residues 306 to 361, molecular weight =
6036.95 Da) was likely not ionized in sufficient quantity
to be detected using our MALDI-TOF instrument had it
existed (Figure 2).
Since the photo-reactive group of the C-28 analog is
further from the triterpene backbone (11 Å, Figure 3A)
than that of the C-30 analog (2.5 Å, Figure 3A) and also
oriented in a different direction from the center of the
molecule, we hypothesized that the two analogs would
crosslink to different locations within the Gag binding
site. Crosslinking experiments with the C-30 analog fol-
lowed by digestion with the three different proteases
were performed as for the C-28 analog. The resulting
mass spectra were also thoroughly analyzed as for the
C-28 analog (Additional File 1: Additional Table 3).
Two experiments with Lys-C digestion of crosslinked C-
30/Gag were conducted. No peptide analog adducts
were observed. However, after Glu-C digestion a peptide
adduct spanning the CA-SP1 cleavage site was found
corresponding to residues 346 to 365
(MMTACQGVGGPGHKARVLA, Figure 4E). The
monoisotopic mass of this ion matched the theoretical
C-30/peptide adduct monoisotopic mass (Table 1). Simi-
larly, Arg-C digestion also revealed one region of cross-
linking, and it too was a peptide fragment spanning CA-
SP1 cleavage site, corresponding to residues 362 to 384
(VLAEAMSQVTNPATIMIQKGNFR, Figure 4F). All
identified crosslinked ions had monoisotopic masses
within +/- 0.015% of theoretical for the C-28 or C-30
peptide adducts (Table 1). These discrepancies from
theoretical monoisotopic masses are well within the
error range of our mass spectrometer, providing confi-
dence in the data.
Comparison of all identified peptide adducts allows us
to infer the region within which binding of the analogs
to Gag must occur (Figure 5A). Since the three different
proteases used in this study produce overlapping pep-
tides, we were able to narrow the region of analog bind-
ing based on overlap of the crosslinked peptides. The C-
28 analog was crosslinked to a five amino acid residue
peptide fragment (DYVDR) of the major homology
region (MHR), and to a twenty-four amino acid residue
peptide fragment (ALGPGATLEEMM-
TACQGVGGPGHK) N-terminal to the CA-SP1
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Figure 4 Details of mass spectra corresponding to predicted
masses for analog-peptide adducts. (A) Lys-C peptide, Gag
residues 336-359, linked to the C-28 analog. (B) Lys-C peptide,
residues 291-302, linked to the C28 analog. (C) Glu-C peptide,
residues 292-307, linked to the C-28 analog. (D) Arg-C peptide,
residues 295-299, linked to the C-28 analog. (E) Glu-C peptide,
residues 346-365, linked to the C-30 analog. (F) Arg-C peptide,
residues 362-384, linked to the C-30 analog.
Table 1 Detailed mass spectra analysis of identified crosslinked peptide fragments
Digestion/
analog
Peptide
Fragment
Theoretical mass + BVM
(+1)
Observed mass
(+1)
% difference from theoretical
mass
Signal/
Noise
Intensity Area
Lys-C/C28 336-359 3210.61 3210.84 0.0072 8.1 2694 1398
Lys-C/C28 291-302 2467.30 2476.57 0.0111 8.5 2728 1318
Glu-C/C28 292-307 2917.57 2917.35 -0.0074 8.3 1480 929
Arg-C/C28 295-299 1508.81 1508.89 0.0055 26.4 19154 4786
Glu-C/C30 346-365 2750.48 2750.60 0.0044 7.2 1978 1298
Arg-C/C30 362-384 3199.79 3199.66 -0.0038 2.9 6317 5231
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linked to a four amino acid segment (VLAE) precisely
spanning the CA-SP1 cleavage site.
Lack of C-28 analog binding to the CA-SP1 region in
bevirimat resistance mutants
We also conducted crosslinking experiments of the C-28
analog to four of the previously characterized bevirimat-
resistant Gag mutants: H358Y, L363M, A364V, and
A366V [10] and to a synthetic Gag mutant ΔM377
[39,42]. We did not observe a crosslinked peptide/C-28
analog adduct within the CA-SP1 region of these Gag
mutants. However, with the exception of A366V, we did
observe such a C-28 analog adduct within the MHR for
all of the mutants. Details of mass spectra analyses of all
non-crosslinked and crosslinked peptide fragments were
also thoroughly analyzed and recorded (Additional File
1: Additional Table 4). The mass spectra data and ana-
lyses of C-28 linked to the MHR (EPFRDYVDRFYK)
peptide of mutants H358Y, L363M, A364V, and ΔM377
are found in Additional File 1: Additional Figure 1 and
Additional File 1: Additional Table 5.
Discussion
The traditional approach to understanding the precise
mechanism of action of a drug is to obtain an atomic
resolution structure by co-crystallization of the drug
bound to its target. A crystal structure of full length
HIV-1 Gag is not yet available [17] and the suspected
target region within Gag is disordered in the available
structures of Gag fragments [29,30]. Therefore the
cross-linking approach offered an alternative way to gain
B 
A 











	
Figure 5 Summary and analysis of analog-peptide adducts. (A) Pictorial representation of all labeled Gag fragments. The SP1 sequence is
indicated in red. The MHR sequence is indicated in brown. The black arrowhead indicates the cleavage site between CA and SP1. Blue and red
underlines represent C-28 and C-30 analog-peptide adducts, respectively; (B) Orientation of bevirimat on its target. Bevirimat is positioned parallel
to the SP1 helix. Residues H358, L363, A364, A366, Q369, A370, and T371 are indicated. The last residue of the C-28 crosslinked region is
indicated in blue, the whole C-30 crosslinked region is indicated in red. The remainder of the sequence is indicated in green. The model is
shown in stick mode and dots show the van der Waals surfaces.
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get. Photoaffinity labeling is a proven and powerful tool
that has been extensively used to gain insight into drug-
binding sites and mechanism of action. Using photoaffi-
nity analogs and mass spectrometry, we were able to
identify peptides that resulted from the crosslinking of
the bevirimat analogs to the bevirimat binding sites
within HIV-1 Gag immature VLP. Two such sites were
identified, one at the CA-SP1 cleavage site and a second
apparent site in the MHR. By employing different pro-
teases and comparing the portions of overlap between
the identified peptide adducts, we were able to narrow
the regions of analog crosslinking. By this method we
determined that the C-30 analog crosslinked within the
four amino acid residues 362-365 spanning the CA-SP1
cleavage site. While only one peptide adduct was identi-
fied in this region with the C-28 analog, it occupies a
site that is upstream from and proximal to the N-term-
inal cleavage site. Thus, we have unambiguously identi-
fied the CA-SP1 cleavage region as a target within Gag
for the maturation inhibitor bevirimat. For the second
binding site, located in the MHR, we were similarly able
to identify a common five amino acid stretch 295-299 as
the location for the adduct linkage with the C-28 analog.
We did not observe a peptide adduct in the MHR for
the C-30 analog.
The use of two analogs with photoaffinity groups pro-
jecting in two different directions from the inhibitor
molecule allowed us to orient the bevirimat triterpene
scaffold along the CA-SP1 helix. The reactive group of
the C-28 analog was crosslinked N-terminal to that of
the C-30 analog. In addition, the small size and
restricted flexibility of the C-30 photoaffinity group con-
strains the positioning of the molecule such that it must
be oriented with the C-28 carboxylic acid group toward
CA and the dimethylsuccinyl group at C3 toward the C-
terminal end of the SP1 helix (Figure 5B). The locations
of the resistance mutant H358Y and the polymorphic
point mutations identified by Adamson et al [43],
Q369H, V370A, and Δ371T, are consistent with this
orientation. It is possible for the oxygen of the C28 car-
boxylic acid group to make a hydrogen bond with the
nitrogen on the sidechain of histidine 358. Similarly, the
two oxygens of the C3 dimethylsuccinyl group could
hydrogen bond with the nitrogen and oxygen on the
glutamine 369 and threonine 371 sidechains, and for
Valine 370 to make a critical hydrophobic contact with
the 3’ methyl groups of the molecule. It is plausible that
changing valine to alanine would disturb an essential
hydrophobic contact between the helix and bevirimat
that makes V370A the most commonly observed resis-
tant polymorphism. The existence of this critical hydro-
phobic interaction is supported by the fact that the
dimethyl group at position 3’ of the molecule enhances
its antiviral activity significantly [9]. Positioning beviri-
mat in this way would place the molecule directly across
the CA-SP1 cleavage site, providing a plausible mechan-
ism by which binding would block access of the viral
protease (Figure 5B).
NMR analyses of peptides spanning the CA-SP1 region
indicates that this region can form an amphipathic a-
helix in 30% TFE [34]. These results led to the interpreta-
tion of cryo-electron tomography data to show the CA-
SP1 region as a six helix bundle in the ordered region of
the immature Gag lattice [26]. The orientations of the
helices within the bundle are unknown, but at least two
plausible configurations are possible (Figure 6). In
hypothetical model A, the hydrophobic and hydrophilic
faces of one helix are making respective contacts with
neighboring helices. Model A might be viewed as a tri-
mer of dimers. In hypothetical model B, the hydrophobic
faces of all six helices are pointing toward the center of
the bundle. The existence of the helical bundle, whatever
the precise configuration, is consistent with the finding
from the in vitro HIV-1 Gag assembly system that beviri-
mat activity requires a higher ordered Gag structure [39].
These results support the idea that the drug’sb i n d i n g
site might consist of more than one helix; more specifi-
cally, bevirimat might bind in the cleft between helices.
This hypothesis is supported by the fact that mutations
or polymorphisms that confer resistance to bevirimat lie
on opposite sides of the helix (for example A364V and
A366V, L363M and H358Y, Q369H and Δ371T). Inter-
estingly, A366V not only is resistant to bevirimat, but
also displays a measure of dependence in high concentra-
tion of the compound [10], further supporting the idea
that this position may represent a site of direct interac-
tion. With these mutants in mind, model A becomes
more plausible as bevirimat can be positioned such that
the hydrophilic and hydrophobic sides of the triterpene
scaffold interact with respective sides of the helices (Fig-
ure 6 left panel, Additional File 1: Additional Table 6).
This model, while hypothetical, offers a starting point for
future investigation to identify residues comprising the
positions of contact.
The identification of a second site for analog cross-
linking in the MHR was unexpected. Two alternative
interpretations are possible: 1) the MHR is a second
independent binding site for bevirimat, or 2) there is
only one binding site at the CA-SP1 cleavage site, but in
the context of assembled Gag the MHR is in close
proximity to this region such that the flexible C-28 reac-
tive group can crosslink to it. The fact that crosslinking
to the MHR was observed for most bevirimat-resistant
mutants supports the idea that the MHR is a second
binding site. Indeed, binding to this region, a well-char-
acterized determinant for assembly in retroviruses
[44-47], would provide a plausible mechanism for the
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Page 8 of 13ability of bevirimat and its precursor, betulinic acid, to
inhibit particle production from cells at high concentra-
tion of compound [5,48]. Alternatively, it is possible that
the MHR and CA-SP1 are in the same vicinity with two
possible binding configurations for the C-28 reactive
compound. The presence of bevirimat resistance muta-
tions could alter the rotational configuration of the C-28
reactive group such that it will favor crosslinking to the
MHR, but not to the peptide fragment (ALGPGATLE-
EMMTACQGVGGPGHK) N-terminal to the CA-SP1
junction (Additional File 1: Additional Figure 2). This
idea is further supported by the fact that the C-30
analog was never found to crosslink to the MHR, which
would be expected if the MHR is an independent bind-
ing site. The cryo-EM model of Wright et al. [26] brings
the MHR into the vicinity of the CA-SP1 helix but the
model was not precisely fitted and remains speculative.
Conclusions
This is the first study to define the molecular target for
the prototypic HIV-1 maturation inhibitor bevirimat.
Although a crystal structure of the entire HIV-1 Gag is
not yet available [17] and the CA-SP1 region was found
to be disordered in subdomain crystallographic studies
Figure 6 Hypothetical models of bevirimat binding to the CA-SP1 junction. Fitting of bevirimat into model A and B according to
crosslinking and mutation data. Since the C-30 analog crosslinked within only four residues (VLAE) spanning the CA-SP1 cleavage site and the C-
28 analog crosslinked within an area four residues upstream from the CA-SP1 cleavage site, we could orient the drug such that the C28
carboxylic acid group is toward the N-terminus and the C3 dimethylsuccinyl group is toward the C-terminus of the helix. Top panel: Top view of
models A&B. In model A, hydrophobic and hydrophilic faces of one helix are making respective contacts with neighboring helices. In model B,
the hydrophobic faces of all six helices are pointing toward the center of the bundle. Bevirimat is shown as gray ball-and-stick atoms. Interacting
amino acids are also shown in ball-and-stick mode; hydrophobic residues are highlighted in red and hydrophilic residues are highlighted in blue.
Models were constructed using six identical NMR structures of a peptide spanning the CA-SP1 region (PDB 1U57). Only sequence spanning the
putative helix was used (GHKARVLAEAMSQVTNSATIMMQR). For simplicity, only sequence HKARVLAEAMSQVTNSAT is shown after the energy
minimization process. Residue H358 is labeled in magenta. The most common in vitro resistant mutation, A364, is labeled in yellow. The most
common resistant polymorphism, V370, is labeled in red. Bottom panel: Side view of models A&B.
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fragment indicated that CA-SP1 is in equilibrium
between random coil and helical states [33]. We propose
that in the context of an immature virion, the equili-
brium of the CA-SP1 region is shifted toward a helical
state that would allow the formation of an ordered heli-
cal bundle. This would allow bevirimat to bind, since it
requires an assembled target [39]. In the absence of bev-
irimat, as the viral protease cleaves MA-CA-SP1 from
nucleocapsid (NC), the equilibrium may gradually shift
toward a random coil. According to this model, the six
helix bundle would become progressively unstructured
from its C-terminal end as each helix opens to an
extend conformation, which then affords the viral pro-
tease access to the scissile bond to cleave SP1 from CA.
Then, as proposed by Wright et al [26], CA-SP1 clea-
vage may lead to expansion of the hexameric lattice of
the mature particle, which would facilitate destabiliza-
tion of the core to prepare the virus for uncoating fol-
lowing entry into the target cell. Binding of bevirimat to
the CA-SP1 junction, however, likely stabilizes the six
helix bundle of CA-SP1, as seen in cryoelectron micro-
scopy analyses of bevirimat-bound budded particles [49],
thereby blocking cleavage by the viral protease. Thus
the critical conformational transformation in the capsid
lattice is blocked, resulting in aberrant core formation
and a non-infectious virus. The information gained from
this study provides critical drug/target details, which in
the absence of crystallographic resolution data for the
CA-SP1 region of Gag, may aid the design and develop-
ment of next-generation maturation inhibitors.
Methods
DNA constructs
pVP-I was derived from plasmid pNL4.3 by modification
to contain a protease active site mutation, a deletion in
pol and a frameshift in env where ‘VP’ stands for virus-
like particles and ‘I’ stands for immature. When trans-
fected into 293T cells this plasmid produces non-infec-
tious immature VLP lacking SU and TM, and
containing nonfunctional RT, IN, and PR [50]. pVP-I
L363M, pVP-I A364V, pVP-I ΔM377, pVP-I A366V,
and pVP-I H358Y were constructed by subcloning the
499-bp Spe-I to ApaI fragment within gag from pNL4.3
L363M, pNL4.3 A364V, pNL4.3 ΔM377, pNL4.3
A366V, and pNL4.3 H358Y into the pVP-I backbone.
pNL4.3 mutants were constructed by site-directed muta-
genesis and were kindly provided to us by Dr. Eric
Freed, National Cancer Institute, National Institutes of
Health. All pVP-I mutants were verified by sequencing.
Photoaffinity analogs
The C-28 photoaffinity analog of bevirimat, PA1050097
or (3b)-28-[4-[(4-azido-2,3,5,6-tetrafluorophenyl)
methyl]-1-piperazinyl]-3-(4-carboxy-3,3-dimethyl-1-oxo-
butoxy)lup-20(29)-en-28-one, was prepared as described
in patent WO 2006053255 [51]. The C-30 photoaffinity
analog, PA1070013 or (3b)-30-azido-3-(4-carboxy-3,3-
dimethyl-1-oxobutoxy)-28-(4-morpholinyl)lup-20(29)-
en-28-one, was prepared from (3b)-3-(4-carboxy-3,3-
dimethyl-1-oxobutoxy)-28-(4-morpholinyl)lup-20(29)-
en-28-one [51] by bromination at the C-30 position with
N-bromosuccinimide in t-butyl methyl ether [52] fol-
lowed by displacement of the resulting allylic bromide
with sodium azide and tetrabutylammonium bromide in
tetrahydrofuran.
Procedure to determine IC50 of the analogs
HIV-1IIIB virus replication inhibition assays were carried
out as follows: The human T-cell line, MT-2 (NIH
AIDS Research and Reference Reagent Program) was
maintained in complete medium (RPMI 1640 with 10%
fetal bovine serum supplemented with L-Glutamine) at
5% CO2 and 37°C. Cells (3 × 10
4 per well) and an
appropriate amount of virus (predetermined by titration
to yield approximately 80% cell killing), were added to
96-well plates containing test compound at appropriate
dilutions. After 5 days in culture, staining with XTT/
PMS viability dye was used to quantify the amount of
virus-mediated cell killing in each well relative to that in
control wells containing no compound. Antiviral activity
was measured as the percent reduction in virus-
mediated cell killing. IC50 values correspond to the test
compound concentrations calculated to result in 50%
reduction in cell killing.
Preparation of Immature VLP
293T cells were cultured in Dulbecco’sm o d i f i e dE a g l e ’s
medium (DMEM) supplemented with 10% fetal bovine
serum, 100 units/mL of penicillin, 100 μg/mL of strepto-
mycin, and 2 mM L-glutamine, at 37°C with 5% CO2.
293T cells at 60%-70% confluence in 150 mm plates
were transfected with 150 μg of pVP-I plasmid per plate
by the calcium phosphate transfection method [53]. Cell
medium was replaced with fresh medium 12 hr post-
transfection. Culture supernatant was collected 48 hr
later and filtered through a 0.45 μm filter. Particles were
concentrated by centrifugation in a Beckman Ti 50.2
rotor at 30,000 rpm for 2 hr. The viral pellet was resus-
pended in 200 μl of phosphate buffered saline (PBS) and
further clarified by centrifugation through a 20% w/w
sucrose cushion at 41,000 rpm for 2 hr in a Beckman
SW-41 rotor, and the resulting pellet was resuspended
in 200 μl of PBS. Naked immature VLP were purified by
treatment of resuspended particles with 1% Triton X-
100 for 15-30 minutes at room temperature followed by
centrifugation through a 20/44% w/w discontinuous
sucrose gradient in a Beckman SW-60 Ti rotor at
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pended in PBS for at least 4 hr to overnight. The
amount of Gag protein in each particle preparation was
quantified using a BSA standard curve generated by
ImageQuant analysis of Gag bands in an SDS-PAGE gel
stained in parallel with a gel containing BSA standards.
Photo-crosslinking of analogs to immature VLP
Each photoaffinity analog was added at a final concen-
tration of 100 μMt o3 0μg of HIV-1 Gag resuspended
in 100 μl of PBS. The reaction mixture was incubated at
30°C for 2 hr with gentle shaking followed by exposure
to a 312 nm UV light box (Fisher Scientific Electrophor-
esis System, Model FBTI81S) for 30 minutes over ice at
a distance of 1 cm from the UV filter. The reaction mix-
ture was then evaporated under vacuum to dryness in a
Speed Vac Concentrator (Thermo Electron Corporation,
Model SPD121P).
Photo-crosslinking of analog to synthetic peptide
The C-28 photoaffinity analog was added to a final con-
centration of 100 μMi na1 0 0μl volume containing 1
mg/ml synthetic peptide. The reaction mixture was
incubated at 30°C for 2 hr with gentle shaking followed
by exposure to a 312 nm UV light box for 30 minutes
o v e ri c ea tad i s t a n c eo f1c mf r o mt h eU Vf i l t e r .T h e
peptide/analog mixture was diluted 50 fold in 50% acet-
onitrile, 0.1% TFA in water and 1 μl was used for
MALDI-TOF analysis.
Reduction, Alkylation and Digestion of Analog/Gag
crosslinked complexes
Completely dried crosslinking reactions were dissolved
and denatured in 6 M urea with brief sonication at
room temperature for 1 minute. The protein was
reduced by adding dithiothreitol to a final concentration
of 5 mM and incubated at 37°C for 1 hr. The alkylation
reaction was carried out by adding iodoacetamide to a
final concentration of 15 mM and incubated at 37°C in
darkness for 1 hr with gentle shaking. Additional DTT
was added to a final concentration of 15 mM and incu-
bated at room temperature for 30 minutes to stop the
alkylation reaction. The concentration of urea was
reduced to 1 M by dilution with appropriate digestion
buffer. Lys-C digestion buffer was 1 M urea, 25 mM
Tris-HCl buffer, pH 8.5, 1 mM EDTA. Lys-C digestion
was carried out at 37°C for 24 hr. Glu-C digestion buffer
was 1 M urea, 25 mM ammonium carbonate buffer, pH
7.8. Glu-C digestion was carried out at 25°C for 24 hr.
Arg-C digestion buffer was 1 M urea, 100 mM Tris-
HCl, 10 mM CaCl2,5m MD T T ,0 . 5m ME D T A ,p H
7.6. Arg-C digestion was carried out at 37°C for 24 hr.
A ratio of 1:30 (w/w) of enzyme/protein was used for
each digestion reaction.
HPLC separation of digestion products
Protease digestion products were evaporated to dryness
under vacuum in a Speed Vac Concentrator and resus-
pended in 250 μl of 20% v/v acetic acid. The suspen-
sion was filtered through a 0.45 μm filter (Costar 8170,
Spin-X centrifuge tube filter) in a microcentrifuge at
13,000 rpm for five minutes before loading onto a 2.1
× 150 mm C18 HPLC column (Higgins Analytical,
Haisil 300 Å, 5 μM). The peptides were eluted with a
15-65% linear gradient of acetonitrile over a period of
80 minutes using a Paradigm MS4B micro-HPLC. Col-
umn effluent was monitored at 215 nm. Eighty 150 μl
fractions were collected per experiment.
Preparation of Matrix-Sample Crystals for MALDI
a-Cyano-4-hydroxycinnamic acid (CHCA) was prepared
as a saturated solution (~10 mg/ml) in 50% acetonitrile
and 0.1%TFA in water. 1 μlo fm a t r i xs o l u t i o nw a s
applied to each sample spot on a 384 well ground steel
target plate and 1 μl of peptide sample solution was
added directly onto the matrix solution. Spots were
dried under vacuum at room temperature. Fresh matrix
solution was prepared for each run.
MALDI-TOF Mass Spectrometry
All mass spectra were obtained on a Bruker Ultraflex II
MALDI-TOF-TOF equipped with the SMART beam
laser. The matrix-assisted laser desorption/ionization
(MALDI) was operated in positive ion, reflector mode.
Ions were generated by a pulsed beam laser (66.7 Hz)
and accelerated to a kinetic energy of 25 kV. External
calibration of the MALDI-TOF was achieved by using
the monoisotopic peaks of a peptide calibration mixture
containing angiotensin II (m/z 1046.542), bombesin (m/
z 1629.823), ACTH (m/z 2465.199), and somatostatin
(m/z 3147.472). Calibration of the instrument was per-
formed before each run.
Peptide synthesis
The peptide GVGGPGHKARVLAEAMSQVTNPATI
spanning the CA-SP1 junction was made by the Univer-
sity of Oklahoma Health Sciences Center Molecular
Biology-Proteomics Facility. The peptide was obtained
by automated solid phase synthesis using Fmoc chemis-
try and purified by reverse phase HPLC. The peptide
was analyzed by mass spectrometry and confirmed to
have purity greater than 98%.
Construction of hypothetical structures
Since the crystal structure of bevirimat was not avail-
able, BVM and its C-28 analogs were modeled using
PyMOL Molecular Graphics System (DeLano Scientific
LLC 2008). The hypothetical helical structures in Figure
6 were constructed in Discovery Studio Client
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Page 11 of 13v2.5.0.9164 using six identical helices. Only the 24 resi-
d u es e q u e n c es p a n n i n gt h eh e l i xs e e ni nN M Re x p e r i -
ments [34] (GHKARVLAEAMSQVTNSATIMMQR,
PDB ID 1U57) was used. The rotational orientation of
individual helices was manually constructed and beviri-
mat was manually docked into the bundle in accordance
with crosslinking data. The complex was energy-opti-
mized using the Standard Dynamic Cascade protocol.
The hypothetical structure shown in Additional File 1:
Additional Figure 2 was created in PyMOL by merging
the common 9 amino acid sequence (LEEMMTACQ) of
the C-terminal domain of CA [29,30] (PDB ID 1AUM)
with that of the NMR structure of the CA-SP1 region
[34] (PDB ID 1U57).
Additional material
Additional file 1: Additional Table 1 - Detail of mass analysis of all
peptide fragments used to generate the peptide map for HIV-1
Gag. Additional Table 2 - Detail of mass analysis of all non-crosslinked
and crosslinked peptide fragments after protease digestion of crosslinked
C-28/Gag. Additional Table 3 - Detail of mass analysis of all non-
crosslinked and crosslinked peptide fragments after protease digestion of
crosslinked C-30/Gag. Additional Table 4 - Detail of mass analysis of all
non-crosslinked and crosslinked peptide fragments after protease
digestion of crosslinked C-28 and mutants Gag. Additional Table 5 -
Detail of mass analysis of C-28 crosslinked MHR (residues 291-302) of
mutants HIV-1 Gag. Additional Table 6 - Contacts between drug and
peptide in model A and model B helices. Additional Figure 1 - Detail of
mass spectra showing ion masses corresponding to the predicted
masses of analog-peptide adducts derived from mutant particles.
Additional Figure 2 - Illustrative cartoon of fused crystallographic
structure of CA C-terminal domain (PDB ID: 1AUM) and NMR structure of
SP1 (PDB ID: 1U57).
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